Download full-text PDF

Source

Publication Analysis

Top Keywords

letter serum
4
serum levels
4
levels estradiol
4
estradiol pregesterone
4
pregesterone administration
4
administration pgf2
4
pgf2 alpha
4
alpha induction
4
induction abortion
4
abortion labour
4

Similar Publications

Response to Letter Entitled "Elevated serum magnesium levels prompt favourable outcomes in cancer patients treated with immune checkpoint blockers".

Eur J Cancer

January 2025

State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine / Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China. Electronic address:

View Article and Find Full Text PDF

Response to letter re: "Elevated serum magnesium levels prompt favourable outcomes in cancer patients treated with immune checkpoint blockers".

Eur J Cancer

January 2025

State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine / Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China. Electronic address:

View Article and Find Full Text PDF

Serum anti-IgLON5 antibodies, which were tested in 223 patients meeting the diagnostic criteria for progressive supranuclear palsy/corticobasal syndrome (PSP/CBS), were negative in all patients. Our study suggests that the frequency of anti-IgLON5 disease is extremely rare in patients with typical presentation of PSP/CBS.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!